[421]
Deaths at home bladder cancer (ISR) all ages by SHA 2002-2004.xls
From [www.bhha.nhs.uk] Last viewed: 11.05.2006
[422]
Cell Cycle Checkpoint Function in Bladder Cancer
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 11.05.2006
[423]
Bladder Cancer in Workers Exposed to Aniline References Response
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 11.05.2006
[424]
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder ...
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 11.05.2006
[425]
Occupational Risks of Bladder Cancer in the United States: II ...
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 11.05.2006
[426]
Information for patients with newly diagnosed bladder cancer
From [www.somerset.nhs.uk] Last viewed: 11.05.2006
[427]
Information for patients with bladder cancer
From [www.somerset.nhs.uk] Last viewed: 11.05.2006
[428]
Advanced Bladder Cancer in a Young Female: A case report
From [mj.med.u-tokai.ac.jp] Last viewed: 11.05.2006
[429]
NON-OCCUPATIONAL RISK FACTORS FOR BLADDER CANCER A CASE-CONTROL STUDY
From [www.tumorionline.it] Last viewed: 11.05.2006
[430]
Blood Donations for Bladder Cancer Research
From [www.forbiztech.com] Last viewed: 11.05.2006
[431]
Cancer Mortality by Proportion Indigenous Population in Queensland ...
From [www.health.qld.gov.au] Last viewed: 11.05.2006
[432]
Characterization of peripheral blood T-cell subpopulation of ...
From [heldref.metapress.com] Last viewed: 11.05.2006
[433]
Notes Acetylator Phenotype, Aminobiphenyl-Hemoglobin Adduct Levels ...
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 11.05.2006
[434]
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder ...
From [dceg.cancer.gov] Last viewed: 11.05.2006
[435]
Bladder cancer
[318,7 KB]
From [www.moh.govt.nz] Last viewed: 23.04.2006
Chapter 9: Bladder cancer
91
Bladder cancer
7KHPDMRUFDXVHVRIEODGGHUFDQFHUDUHWKRXJKWWREHWREDFFRVPRNLQJDQGRFFXSDWLRQDO
FKHPLFDO H[SRVXUH LQ WKH UXEEHU RUJDQLF G\H PHWDO UHILQLQJ SHWURFKHPLFDO DQG SDLQW
LQGXVWULHV 'HSDUWPHQWRI+HDOWK 7KHDHWLRORJ\RIPDQ\FDVHVLVXQNQRZQ
2YHU WKH SHULRG WR WKH DYHUDJH DQQXDO DJH VWDQGDUGLVHG LQFLGHQFH UDWH RI
EODGGHU FDQFHU LQFUHDVHG E\ PRUH WKDQ IURP SHU WR SHU
DPRQJPDOHV DQGIURP SHU WR SHU DPRQJIHPDOHV 2YHUWKHVDPH
SHULRGWKHDEVROXWHQXPEHURIDQQXDOUHJLVWUDWLRQVLQFUHDVHGPRUHWKDQILYH IROG IURP
WR UHJLVWUDWLRQVDPRQJPDOHVDQGIURP WR UHJLVWUDWLRQVDPRQJIHPDOHV 7KH
LQFUHDVLQJ ULVN RI EODGGHU FDQFHU RYHU WKH \HDU SHULRG ZDV UHVSRQVLEOH IRU RQO\
DSSUR[LPDWHO\RQH WKLUGRIWKHLQFUHDVHLQWKHQXPEHURIUHJLVWUDWLRQV ERWKJHQGHUV ZLWK
WKHUHPDLQGHURIWKHLQFUHDVHLQEXUGHQEHLQJH[SODLQHGE\GHPRJUDSKLFWUHQGV PDLQO\WKH
LQFUHDVHWKDWRFFXUUHGLQSRSXODWLRQVL]H
%\FRQWUDVW PRUWDOLW\IU...
[436]
Survival Drops When Bladder Cancer Surgery Is Deferred
[16,0 KB]
From [www.matritech.com] Last viewed: 23.04.2006
[437]
Bladder tumor antigen sensitivity in bladder cancer patients
[84,2 KB]
From [www.halic.edu.tr] Last viewed: 23.04.2006
Journal of Cell and Molecular Biology 3: 51-119, 2004.
Haliç University, Printed in Turkey.
51
Bladder tumor antigen sensitivity in bladder cancer patients
Soner Güney, Serdar Arisan*, ‹brahim Duman, Turhan Çaflkurlu, Cem Sönmez,
Erbil Ergenekon
fiiflli Etfal Research and Training Hospital, 1
st
Urology Clinics, fiiflli-Istanbul, Turkey (*author for
correspondence)
Received 19 December 2003; Accepted 26 January 2004
Abstract
With its incidence continuing to increase, bladder cancer is now the fifth most common cancer in the world.
Approximately half of these patients will have muscle-invasive disease at diagnosis and have distant metastasis
within 2 years and 60% die within 5 years despite treatment. Therefore, rapid and sensitive urine based markers are
still under investigation. In this study, we aim to find the BTA stat results for 259 Turkish patients (200 ...
[438]
Why he gets bladder cancer again after the treatments?
[42,2 KB]
From [www1.naturvetenskap.lu.se] Last viewed: 23.04.2006
Wipatorn von Heiroth
Why he gets bladder cancer again after the treatments?
Bladder cancer is the 6
th
most common cancer in men and the 9
th
in women. Most bladder
cancers develop in the lining of the bladder . Bladder cancer begins from one cell, which has
genetic change. Due to the genetic changing that cell produces many enzymes, which affect
the nearby cells, resulting in the spreading through the lining of the bladder to the muscle or
spread to near-by organs and the lymph system. The abnormal cells that are located in the
surface of the bladder are called superficial bladder tumour and the ones that penetrate
deeper into the muscle are called invasive bladder cancer . Figure shows the developing of
the tumour cells.
Figure: The development of bladder tumours cells: 1; the abnormal genetic cell 2;
cells with more genetic change, ...
[439]
Bladder cancer and other urothelial tumours
[81,1 KB]
From [www.rcr.ac.uk] Last viewed: 23.04.2006
[440]
Arsenic Ingestion and Bladder Cancer Mortality - What Do the Dose ...
[2975,9 KB]
From [www.woodpreservativescience.org] Last viewed: 23.04.2006
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Arsenic Ingestion and Bladder Cancer Mortality - What Do the Dose-Response Re
Steven H Lamm; Michael B Kruse
Human and Ecological Risk Assessment; Apr 2005; 11, 2; Sciences Module
pg. 433
Page 2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Page 3
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Page 4
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Page 5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Page 6
Reproduced with permission ...
[441]
Anti-Bladder Cancer Activity of GCP
[1116,6 KB]
From [www.integrativeonc.org] Last viewed: 23.04.2006
Center for Holistic Urology, Columbia University
p53 Gene Status as a Determinant
p53 Gene Status as a Determinant
in GCP
in GCP
™
™ Effectiveness Against
Effectiveness Against
Bladder Cancer
Bladder Cancer
Debra L. Bemis, Ph.D.
Center for Holistic Urology
Columbia University
New York, NY
Page 2
Center for Holistic Urology, Columbia University
Bladder Cancer (BlCa)
63,210 estimated new cases of BlCa for 2005 in the U.S. *
Smoking is the strongest environmental risk factor
- 50% of bladder tumors in men are attributable to smoking
Incidence is 6 times greater in US than Japan, but twice as
many men smoke in Japan compared to US
- Genetic susceptibility
- Lifestyle / Dietary factors: Soy isoflavones
*American ...
[442]
Predicting Response to Intravesical Therapy for Superficial ...
[342,7 KB]
From [www.mdanderson.org] Last viewed: 23.04.2006
FALL 2005/ WINTER 2006
Predicting Response to Intravesical
Therapy for Superficial Bladder Cancer
The Genitourinary Cancer Center
brings together highly qualified
clinical and research faculty and
staff committed to eliminating
the morbidity and mortality of
genitourinary cancers. Each
faculty member represents the
highest standard of excellence
in his/her own field. Working
together, we are dedicated to
achieving our common Mission.
To create a seamless research and clinical
care integration that enables
the rapid application of
research to relevant clinical
problems and the immediate
translation of scientific discovery to
cancer interventions and therapies.
Mission
• • •
AREAS OF intERESt
Genitourinary Cancer Center
physicians treat the following cancers: ...
[443]
Screening for Bladder Cancer
[72,6 KB]
From [www.phac-aspc.gc.ca] Last viewed: 23.04.2006
Screening
for
Bladder
Cancer
C
HAPTER
68
By Sarvesh Logsetty
Page 2
Screening for Bladder Cancer
68
Prepared by Sarvesh Logsetty, MD
1
I
n 1 979 the Canadian Task Force on the Periodic Health
Examination addressed the question of screening for bladder
cancer in the periodic health examination. The screening tool
considered was urine cytology, and it was recommended that the
general population not be screened (D Recommendation). The
screening of high-risk groups, however, was recommended
(B Recommendation) pending further information.< 1 > The
current Task Force recommendations for urine screening for
microscopic hematuria and urine cytology are a D
Recommendation for the general population and a C
Recommendation ...
[444]
Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a ...
[205,0 KB]
From [som.ucdavis.edu] Last viewed: 23.04.2006
ReviewöBladder Cancer
Neoadjuvant Chemotherapy in Invasive Bladder Cancer :
Update of a Systematic Review and Meta-Analysis of
Individual Patient Data
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration
Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Accepted 6 April 2005
Available online 21 April 2005
Abstract
Objectives: To update a systematic review and meta-analysis that assesses the effect of neoadjuvant chemotherapy in
the treatment of patients with invasive bladder cancer .
Methods: Following a prespecified protocol, we analysed updated individual patient data from all eligible
randomised controlled trials that compared neoadjuvant chemotherapy plus local treatment with the same local
treatment alone.
Results: Updated results are based on 11 trials, 3005 patients; comprising 98% of all ...
[445]
Adjuvant Chemotherapy in Invasive Bladder Cancer: ASystematic ...
[378,2 KB]
From [som.ucdavis.edu] Last viewed: 23.04.2006
ReviewöBladder Cancer
Adjuvant Chemotherapy in Invasive Bladder Cancer :
ASystematic Review and Meta-Analysis of Individual
Patient Data
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration
Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Accepted 6 April 2005
Available online 25 April 2005
Abstract
Objectives: To evaluate the effect of adjuvant chemotherapy in invasive bladder cancer .
Methods: We conducted a systematic review and meta-analysis of updated individual patient data from all available
randomised controlled trials comparing local treatment plus adjuvant chemotherapy versus the same local treatment
alone.
Results: Analyses were based on 491 patients from six trials, representing 90% of all patients randomised in
cisplatin-based combination chemotherapy trials and 66% of patients from all ...
[446]
BLADDER CANCER:
[78,5 KB]
From [www.theralogix.com] Last viewed: 23.04.2006
BLADDER
CANCER :
REDUCING
THE RISK OF
RECURRENCE
B
ladder cancer is the fourth most
common cancer in men, and the
ninth most common cancer in women
in the United States. It is estimated
that 63,210 new cases of bladder
cancer will be diagnosed in the U.S.
during 2005.Although a number of
factors are believed to increase the
risk of developing bladder cancer ,
cigarette smoking is – by far – the
biggest single risk factor.
Symptoms of bladder cancer can
include blood in the urine, painful
urination and increased frequency
of urination.
For more information,
speak to your urologist.
Nutritional Supplementation
In the early 1990’s, Donald Lamm, M.D., a leading
bladder cancer researcher, conducted a prospective,
randomized, double-blind clinical trial testing the ...
[447]
CANCER URINARY BLADDER ETIOPATHOLOGY & ITS MANAGEMENT
[91,6 KB]
From [medind.nic.in] Last viewed: 23.04.2006
126
INCIDENCE
In men it is the fourth most common cancer after
prostate, lungs, colorectal malignancy accounting for
6.2% of all cancer cases. In women it is the eighth
most common cancer accounting for 2.5% of all cancer
cases.
Bladder cancer is the second most common
urological malignancy after prostate cancer in males.
RACE
Bladder cancer is roughly two times as common
among American white men as among American black
men and is only roughly 1.5 times more common among
white American than black American women.
RATIO
The male to female ratio is 3:1.
AGE
Bladder cancer can occur at any age even in
children. It usually occurs in the 4th to 5th decade of
life but in the last one decade we often see this
malignancy occurring in younger age group also -
thanks to rapid industrialization. Younger patients
appear to have more favourable ...
[448]
GALL BLADDER CANCER ETIOPATHOLOGY AND TREATMENT
[110,4 KB]
From [medind.nic.in] Last viewed: 23.04.2006
134
Carcinoma gall bladder has an unusual
geographic distribution. While it is uncommon in
Europe and the United States, it is more frequent in
Chile, Bolivia and Israel (Orth and Berger, 2000). The
incidence of carcinoma gall bladder in India ranges
from 1.01 per 100000 for males to 10.1 per 100000 for
females (ICMR 1996) but the actual number may be
much more in the endemic zones of Western Bihar and
Eastern Uttar Pradesh where it is the third commonest
malignancy of the alimentary tract (Shukla et. al.
1985). Due to its non specific clinical presentation, it
is seldom diagnosed preoperatively except in advanced
cases. Survival depends on the ability to achieve a
curative resection depending upon the stage of the
disease. The overall surgical resection rates range
from 10% to 30% only thereby indicating a poor
prognosis. The aetiology of carcinoma gall bladder is
poorly understood. ...
[449]
Bladder cancer in England_Cover.psd
[1439,9 KB]
From [www.uhce.ox.ac.uk] Last viewed: 23.04.2006
Page 2
Bladder cancer in England 1998/9 to 2002/3.
A geographical profile of hospital admissions.
Authors: Michael Goldacre, David Yeates, Leicester Gill,
Henry McGuinness, Daniel Meddings
Published by: Unit of Health-Care Epidemiology, Oxford University, and
South East England Public Health Observatory, 2005
This document provides a geographical profile of hospital admission for
bladder cancer in England. The geographical areas covered are the standard
local authority areas of England. The period covered is April 1 1998 to March
31 2003. The data are from Hospital Episode Statistics (HES). HES includes
data on all NHS hospital admissions (including admissions for day case
care). This analysis includes HES data about men and women of all ages.
The maps show:
(a) The spell-based admission rates per 100,000 resident population for
each local authority per ...
[450]
Moores bill encourages bladder cancer screening for all ...
[37,7 KB]
From [www.matritech.com] Last viewed: 23.04.2006
FOR IMMEDIATE RELEASE
August 2, 2005
Moore’s bill encourages bladder cancer
screening for all firefighters in the state
BOSTON – Legislation sponsored by Senator Richard T. Moore (D-Uxbridge) that establishes a bladder
cancer screening program within the Department of Public Health (DPH) was given a favorable report by
the Committee on Health Care Financing today.
“This bill aims to encourage firefighters to get screened for bladder cancer every year,” said Senator
Moore. “It is extremely important to detect bladder cancer early. The survival rate is much higher. In
addition, with the data collected through this program, the state can educate and prevent bladder cancer
to certain high risk groups.”
Senate bill 1301 requires the commissioner of the DPH to establish, promote, and maintain a public
information program regarding the incidence of bladder cancer in professional ...
Found 1306 documents
Page 15 of 44 Pages:
<< < 10 11 12 13 14 15 16 17 18 19 20 > >>
cancers
homepage
last week